Glenmark Pharma launches Evoclin Foam's bioequivalent in US
Glenmark Pharmaceuticals has announced the launch of Clindamycin Phosphate Foam, which is a bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam of Mylan Pharmaceuticals Inc.
Clindamycin Phosphate Foam is a medication used to treat acne vulgaris in patients 12 years and older.
According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, market achieved annual sales of approximately $5.8 million.
Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses.
The drug maker had reported a consolidated net profit of Rs 354.21 crore in Q2 FY25 as against net loss of Rs 81.95 crore in Q2 FY24. Revenue from operations increased 7.59% year on year (YoY) to Rs 3,400.50 crore in the quarter ended 30 September 2024.
The scrip fell 2.82% to currently trade at Rs 1411.60 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Feb 12 2025 | 10:21 AM IST